Background: We intended to observe the effects of different doses of remimazolam besylate via intravenous induction on the quality of sedation and cardiac function in elderly patients.
Methods: A total of 135 ASA I-III patients undergoing elective laparoscopic cholecystectomy were selected. They were divided into three groups and they were randomized. Low dose group (Group L): Remimazolam besylate 0.2 mg/kg; middle dose group (Group M): Remimazolam besylate 0.3 mg/kg; High dose group (Group H): Remimazolam besylate 0.4 mg/kg. There were 45 patients in each group. The blood pressure, heart rate, BIS values, cardiac function before induction (T), after induction (T) and after intubation (T), as well as the length of loss of consciousness, duration of sedation, and extubation and adverse events were recorded.
Results: At T and T, systolic and diastolic blood pressure in Group M were lower than those in Group L, but higher than those in Group H, with statistically significant differences ( < 0.05). At T and T, the BIS value in Group M was lower than that in Group L, with a statistically significant difference ( < 0.05). However, there was no statistically significant difference ( 005) in BIS values between Group M and Group H; At T and T, the cardiac output and stroke volume in Group M were higher than those in Group H, while the systemic vascular resistance in Group M was lower than that in Group H, with statistically significant differences ( < 0.05); The incidences of bucking when moving and hiccup in Group L were higher than those in Group M and Group H, with statistically significant differences ( < 0.05). The number of vasoactive drugs used in Group H was higher than that in Group L and Group M, with statistically significant differences ( < 0.05).
Conclusions: General anesthesia induction with remimazolam besylate at 0.3 mg/kg in elderly patients undergoing laparoscopic cholecystectomy showed good quality of sedation, could achieve rapid intubation, with minimal effect on cardiac function and generally favorable safety profile.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11743649 | PMC |
http://dx.doi.org/10.3389/fcvm.2024.1453608 | DOI Listing |
Front Cardiovasc Med
January 2025
Department of Anesthesiology, The First Affiliated Hospital of Anhui University of Science and Technology, Huainan, Anhui, China.
Background: We intended to observe the effects of different doses of remimazolam besylate via intravenous induction on the quality of sedation and cardiac function in elderly patients.
Methods: A total of 135 ASA I-III patients undergoing elective laparoscopic cholecystectomy were selected. They were divided into three groups and they were randomized.
BMJ Open
November 2024
Department of Anaesthesiology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
BMC Anesthesiol
October 2024
Department of Anesthesiology, Weifang People's Hospital, No. 151 Guangwen Street, Kuiwen District, Weifang, 261041, China.
Cureus
September 2024
Department of Anesthesiology and Perioperative Medicine, MD Anderson Cancer Center, Houston, USA.
Remimazolam besylate is a novel, rapid-onset, ultra-short-acting benzodiazepine with an advantageous cardio-respiratory safety profile. To date, there have been few published reports of remimazolam-induced anaphylaxis, none of which are documented in patients with mast cell disease. We describe the case of a 77-year-old male with oncologic mastocytosis who developed anaphylaxis following remimazolam administration.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!